RxDoctor Payments Data

Biswajit Banik, MD

Clinical Neurophysiology · Columbia, SCNPI 1568997708

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 20 payments — averaging $59.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$310
  • AstraZeneca$152
  • Biogen$150
  • SK Life Science, Inc.$117
  • Imperative Care, Inc$108
  • Tanabe Pharma America, Inc.$100
  • plus $252 from 7 others

What the payments were for

  • Consulting fees$15013%
  • Food & beverage$1,03987%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few clinical neurophysiology providers in South Carolinato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$110,771
Medicare patients
246
Services billed
5,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant13$14,816
Pregabalin143$4,804
Mycophenolate Mofetil27$1,553
Pyridostigmine Bromide38$1,416
Gabapentin88$1,224
Duloxetine Hcl53$986
Primidone11$823
Oxcarbazepine16$747
Baclofen59$477
Topiramate60$463
RizatriptanRizatriptan Benzoate40$423
Levetiracetam19$337
Sumatriptan Succinate39$321
Propranolol Hcl13$213
Prednisone22$99

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy$66$14,81613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few clinical neurophysiology providers in South Carolinaon file to place this against a meaningful peer group, so we don't.

Other clinical neurophysiology in Columbia

Where these figures come from

Is this you, or does something look wrong? →